This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

R. Mark Evans, PhD
Program on Drugs American Medical Association Chicago

JAMA. 1985;254(8):1033-1034.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

As staff scientist to the Council on Scientific Affairs, I researched and prepared the report entitled "Guidelines for Handling Parenteral Antineoplastics." Randall and Constable are concerned that readers might infer from the introduction to this report that combined chemotherapy and radiation may lead to a higher risk of secondary nonlymphocytic leukemia than chemotherapy alone. Careful reading of the text shows that we did not imply that risks were higher. The statement that patients received radiation therapy was included in an attempt to describe further the therapeutic intervention. Randall and Constable are correct in that not all patients in one of our references (Am J Med 1983; 75:449-454) received radiation in addition to MOPP therapy (Mustargen [mechlorethamine hydrochloride], Oncovin [vincristine sulfate], procarbazine, and prednisone).

However, I strongly object to the language of the last paragraph of their letter. This is an attempt to embroil this report in the controversial . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?